Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine and Busulfan Conditioning for Allo-HSCT
NCT00556452Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2007
- Primary completion
- Jun 2011
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine in acute leukemia, Chronic Myeloid Leukemia (CML), myelodysplastic syndrome (MDS) and 4 more, sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Regimen Related Toxicities at 2 years and One-year Overall Survival Rate for AML at 1 year. Started Oct 2007; status: completed.
02
Drugs
clofarabine
03
Conditions
acute leukemiaChronic Myeloid Leukemia (CML)myelodysplastic syndrome (MDS)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00556452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00556452.